Vanguard Global Advisers’s CytomX Therapeutics CTMX Stock Holding History
Bought
Maintained
Sold
Other funds holding CTMX
KCM
Vanguard Global Advisers's CTMX Position: Q3 2026 in Review
Vanguard Global Advisers increased its CytomX Therapeutics (CTMX) stake by 14% in Q3 2026, buying an estimated $33.2K and bringing the position to 81,583 shares worth $222K. The position accounts for ﹤0.01% of the portfolio, ranked #2446.
Vanguard Global Advisers first reported a position in CTMX in Q1 2026 and has held it in 3 quarters since. The position peaked at $337K in Q1 2026. 194 funds tracked by Wall St. Rank hold CTMX as of Q3 2026.
- Vanguard Global Advisers held 81,583 shares of CytomX Therapeutics worth $222K as of Q3 2026.
- Vanguard Global Advisers bought 9,966 CytomX Therapeutics shares in Q3 2026, an estimated $33.2K.
- CytomX Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2446 holding.
- Vanguard Global Advisers first reported a position in CytomX Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Global Advisers's CytomX Therapeutics position peaked at $337K in Q1 2026.
- 194 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.